Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TSE Research Core Facility Would Reduce Risks, Funding Hurdles - Rohwer

This article was originally published in The Gray Sheet

Executive Summary

HHS should help fund a "core facility" for transmissible spongiform encephalopathy (TSE) research that will facilitate development of a TSE assay, according to Robert Rohwer, PhD, TSE Resources, Inc., Columbia.

You may also be interested in...



Prion Research Should Focus On Diagnostics, Infrastructure – IoM

Development of effective diagnostics and additional research infrastructure in the field of prion science, as well as expanding basic research, are highlighted as priority areas for the Department of Defense National Prion Research Program in an interim IoM report

Who’s Hired? Hikma Recruits New US Generics President

A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015474

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel